Title: Variation of Prolidase Activity: A Predictor of Neuropathy due to Diabetes Mellitus?
Authors: Dr Jayanta Kumar Rout, Dr Amrita Mukherjee, Dr Sandeep Jain, Angshuman Mukherjee
DOI: https://dx.doi.org/10.18535/jmscr/v5i2.153
Abstract
Prolidase is a member of the matrix metalloproteinase family responsible for collagen turnover which is implicated in the pathogenesis of diabetic neuropathy (DN). 50 (F-16, M-34) subjects suffering from T2DM, 46 subjects (F-21, M-25) with DN and 50 (F-19, M-31) healthy volunteers were selected to evaluate if there is any role of altered plasma prolidase activity in the development of diabetic neuropathy. HOMA-IR was applied for estimation of insulin resistance and NCV was performed to confirm the subjects of neuropathy. Estimation of prolidase activity was based on the principle proposed by Myara et al. (1984).No significant correlation between prolidase activity and HOMA-IR in the control group and group 1 categorized as patients of T2DM without any microvascular complications was found statistically. However in patients of T2DM with neuropathy (group 2) we found a significant correlation (r=0.324, p=0.028). Independent sample t-test between healthy control and group1 reveals statistically significant change of mean levels of HOMA IR (t=7.174, p<0.001) but not of prolidase (t=1.174, p=0.243) activity. Using t-test again between group 1 and 2 we found that the parameters HOMA-IR (t=4.643, p<0.001) and prolidase (t=5.968, p<0.001) were significantly higher in group 2 than in group 1. These findings imply a strong association between insulin resistance and increased collagen turnover in T2DM. ANOVA was performed and a strong statistical association was found in case of HOMA-IR (F=50.266, p<0.001) and prolidase activity (F=31.006, p<0.001) among different groups. These findings can hypothesize that collagen turnover and increased insulin resistance are possibly the underlying pathogenic mechanisms for the development of neuropathy caused by diabetes.
Keywords: prolidase; collagen turnover; diabetes mellitus; diabetic neuropathy; homa ir.
References
1. Becker M, Benromano T, Shahar A, Nevo Z, Pick CG. Changes in the Basal Membrane of Dorsal Root Ganglia Schwann Cells Explain the Biphasic Pattern of the Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats. J Mol Neurosci2014 Sep 27.
2. Albers JW, Pop-Busui R. Diabetic neurop-athy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep2014 Aug;14(8):473.
3. Gupta A, Gupta Y. Diabetic neuropathy: Part 2. J Pak Med Assoc2014 Jul;64(7):846-50.
4. Gupta A, Gupta Y. Diabetic neuropathy: Part 1. J Pak Med Assoc2014 Jun;64(6):714-8.
5. Pirincci N, Kaba M, Gecit I, Gunes M, Yuksel MB, Tanik S, Arslan A, Demir H. Serum prolidase activity, oxidative stress, and antioxidant enzyme levels in patients with renal cell carcinoma. Toxicol Ind Health2013 Sep 30.
6. Yuan J, Li T, Yin XB, Guo L, Jiang X, Jin W, Yang X, Wang E. Characterization of prolidase activity using capillary electrophoresis with tris(2,2'-bipyridyl)ruthenium(II) electrochemiluminescence detection and application to evaluate collagen degradation in diabetes mellitus. Anal Chem2006 May 1;78(9):2934-8.
7. Besio R, Gioia R, Cossu F, Monzani E, Nicolis S, Cucca L, Profumo A, Casella L, Tenni R, Bolognesi M, Rossi A, Forlino A. Kinetic and structural evidences on human prolidase pathological mutants suggest strategies for enzyme functional rescue. PLoS One2013;8(3):e58792.
8. Sabuncu T, Boduroglu O, Eren MA, Torun AN, Aksoy N. The Value of Serum Prolidase Activity in Progression of Microalbuminuria in Patients With Type 2 Diabetes Mellitus. J Clin Lab Anal2015 Dec 14.
9. Erbagci AB, Araz M, Erbagci A, Tarakcioglu M, Namiduru ES. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin Biochem2002 Jun;35(4):263-8.
10. Uzar E, Tamam Y, Evliyaoglu O, Tuzcu A, Beyaz C, Acar A, Aydin B, Tasdemir N. Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci2012 Aug;33(4):875-80.
11. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care1997 Jul;20(7):1087-92.
12. Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care1997 Oct;20(10):1562-8.
13. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care2000 Mar;23(3):295-301.
14. Dasgupta A, Singh OP, Rout JK, Saha T, Mandal S. Insulin resistance and metabolic profile in antipsychotic naive schizop-hrenia patients. Prog Neuropsychoph-armacol Biol Psychiatry2010 Oct 1;34(7):1202-7.
15. Sayin R, Aslan M, Kucukoglu ME, Luleci A, Atmaca M, Esen R, Demir H. Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine2014 Sep;47(1): 146-51.
16. Diagnosis and classification of diabetes mellitus. Diabetes Care2007 Jan;30 Suppl 1:S42-7.
17. Golembiewska E. [Diagnostic value of fasting glucose, fructosamine, and glycated haemoglobin HbA(1c) with regard to ADA 1997 and who 1998 criteria for detecting diabetes and other glucose tolerance abnormalities]. Ann Acad Med Stetin2004;50(1):131-8.
18. Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res Clin Pract2011 Dec;94(3):322-32.
19. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc2009 Jun;107(6):403-5.
20. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. New Delhi: Saunders,Elsevier; 2006. p. 870-1.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985 Jul;28(7):412-9.
22. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care2004 Jun;27(6):1487-95.
23. Francisco G, Hernandez C, Galard R, Simo R. Usefulness of homeostasis model assessment for identifying subjects at risk for hypoglycemia failure during the insulin hypoglycemia test. J Clin Endocrinol Metab2004 Jul;89(7):3408-12.
24. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem1984 Feb;30(2):211-5.
25. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep2014 Sep;14(9):528.